Biodexa Pharmaceuticals Plc (BDRX)
| Market Cap | 1.58M -62.2% |
| Revenue (ttm) | n/a |
| Net Income | -8.59M |
| EPS | -78.31 |
| Shares Out | 1.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 24,453 |
| Open | 1.490 |
| Previous Close | 1.470 |
| Day's Range | 1.400 - 1.680 |
| 52-Week Range | 1.020 - 59.400 |
| Beta | 1.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About BDRX
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse m... [Read more]
News
Biodexa Pharmaceuticals Registration statement: Registration filing
Biodexa Pharmaceuticals filed a registration statement on July 30, 2026, providing details about a securities offering with the SEC.
Result of General Meeting
July 29, 2026 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innov...
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
July 28, 2026 Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing in...
Biodexa Pharmaceuticals Registration statement: Registration filing
Biodexa Pharmaceuticals filed a registration statement on July 15, 2026, providing details about a securities offering with the SEC.
Result of Annual General Meeting
June 30, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopha...
Biodexa Pharmaceuticals announces pricing of $3.5M registered offering
Biodexa Pharmaceuticals (BDRX) announced the pricing of a $0.8M registered offering, a $1M concurrent private placement, and a $1.7M warrant inducement utilizing existing share capital authorities. Th...
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
June 30, 2026 Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biod...
Biodexa Pharmaceuticals receives Health Canada approval for Serenta trial
Biodexa Pharmaceuticals (BDRX) announced that it has received approval from Health Canada to expand its registrational Phase 3 trial in familial adenomatous polyposis into Canada. The Phase 3 study, b...
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), ...
Postponement and Re-scheduling of Annual General Meeting
June 17, 2026 Biodexa Pharmaceuticals PLC Postponement and Re-scheduling of Annual General Meeting Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutic...
Biodexa issues letter to Shareholders
May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or pre...
Biodexa Pharmaceuticals PLC-ADR trading halted, news pending
19:50 EDT Biodexa Pharmaceuticals (BDRX) PLC-ADR trading halted, news pending
Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene
Biodexa Pharmaceuticals (BDRX) announced that it has partnered with Syngene for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form.
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
April 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biophar...
Biodexa, Tanner Pharma launch global early access program for FAP patients
Tanner Pharma Group and Biodexa Pharmaceuticals (BDRX) have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis, FAP, through an Early A...
Preliminary Results for the Year Ended 31 December 2025
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals ...
Biodexa Pharmaceuticals management to meet with Maxim
Meeting to be held on March 23-27 hosted by Maxim.
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical sta...
Biodexa Pharmaceuticals announces one-for-five reverse ADR split
Biodexa Pharmaceuticals (BDRX) announced a ratio change on its American Depositary Receipts from one ADR representing 100,000 ordinary shares, to the new ratio of one ADR representing 500,000 ordinary...
ADR Ratio Change
March 18, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of...
Biodexa Pharmaceuticals supports Life’s a Polyp Foundation
Biodexa Pharmaceuticals (BDRX) is pleased to recognise Life’s a Polyp Foundation on its official launch following an initial financial grant from Biodexa to support the organization’s vital work empow...
Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
March 9, 2026 Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a cli...
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 20...
Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical
Biodexa Pharmaceuticals (BDRX) announced the closing of an exclusive license with Otsuka Pharmaceutical for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointes...
Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models ...